

# PROVIDER Update



CONTRACTUAL | OCTOBER 24, 2022 | UPDATE 22-898 | 2 PAGES

## Know What's New and Changing: 2023 Prior Authorization List

### Drugs that require prior authorization now and other changes that start January 1, 2023

The below medical benefit medications require prior authorization (PA) for all lines of business per new HCPCS codes issued by the Centers for Medicare & Medicaid Services effective October 1, 2022.

Code	Description
C9142	Injection, bevacizumab-maly, biosimilar, (Alymsys®), 10 mg
J1302	Injection, sutimlimab-jome, 10 mg
J1932	Injection, lanreotide, (Cipla), 1 mg
J2777	Injection, faricimab-svoa, 0.1 mg
J9274	Injection, tebentafusp-tebn, 1 mcg
J9298	Injection, nivolumab and relatlimab-rmbw, 3 mg/1 mg
Q2056	Ciltacabtagene autoleucel, up to 100 million autologous B-cell maturation antigen (BCMA) directed CAR-positive T cells, including leukapheresis and dose preparation procedures, per therapeutic dose
Q5125	Injection, filgrastim-ayow, biosimilar, (Releuko®), 1 mcg

#### Additional information

If you have questions regarding the information contained in this update, contact CalViva Health at 888-893-1569.

#### THIS UPDATE APPLIES TO MEDI-CAL PROVIDERS:

- Physicians
- Participating Physician Groups
- Hospitals
- Ancillary Providers
- Community Supports Providers
- Enhanced Care Management Providers

#### PROVIDER SERVICES

888-893-1569  
[www.healthnet.com](http://www.healthnet.com)

#### PROVIDER PORTAL

[provider.healthnetcalifornia.com](http://provider.healthnetcalifornia.com)

## 2023 New services for Community Supports, Long-Term Care and more

View the table, which starts below, for prior authorization (PA) requirement changes for Health Net\* and CalViva Health Medi-Cal fee-for-service providers.

Requirement	Comments	Adult members ages 21+	Pediatric members under age 21
<b>Additions, effective January 1, 2023</b>			
Community Supports <ul style="list-style-type: none"> <li>Community transition services/nursing facility transition to a home</li> <li>Day habilitation</li> <li>Nursing facility transition/diversion to assisted living facilities</li> <li>Personal care and homemaker services</li> <li>Respite services</li> <li>Short-term post-hospitalization housing</li> </ul>	Refer to the CalAIM Resources for Providers page on the portal at healthnet.com > <i>Providers &gt; CALAIM RESOURCES.</i>	New	New
Outpatient Pharmaceuticals (submitted under Medical Plan)	Histrelin acetate	New	New
Wound care	Including but not limited to: <ul style="list-style-type: none"> <li>Negative pressure wound treatment, low-frequency ultrasound.</li> <li>Skin substitute and biologicals.</li> <li>Wound debridement – authorization required after 12 sessions per year.</li> </ul>	New	New
<b>Changes, effective January 1, 2023</b>			
Avsola®	Avsola is no longer a preferred biosimilar to Remicade®.	New	New
Bevacizumab agents	Now require authorization for all providers – previously limited to non-ophthalmologist only.	New	New
Long-term care nursing facility admissions	<ul style="list-style-type: none"> <li>Previously available only for the month of admission and month after admission. Effective 1/1/2023 medically necessary services will be available for all adult Medi-Cal members.</li> <li>Contact the Long-Term Care Intake Line.</li> </ul>	New	N/A